In metastatic prostate cancer, strong MEK5 expression is correlated with bony metastases, and less favorable prognosis is caused by upregulated BMK1-induced activator protein-1 (AP-1) activity, a consequent induction of a high level of matrix metallo-protease-9 (MMP-9) and augmented invasive potential [11]. The gene discussed is MAP2K5; the disease is metastatic prostate carcinoma.